[Cytokines in bone diseases. BMP signaling and fibrodysplasia ossificans progressiva]

Clin Calcium. 2010 Oct;20(10):1510-7.
[Article in Japanese]

Abstract

Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder characterized by progressive heterotopic bone formation in skeletal muscle tissue. In 2007, FOP was authorized as one of the Intractable Disorders by the Ministry of Health, Labour and Welfare of Japan. The Research Committee on FOP is working on the molecular mechanisms underlying heterotopic bone formation and the development of new treatments for FOP.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Activin Receptors, Type I / genetics
  • Activin Receptors, Type I / metabolism
  • Bone Morphogenetic Proteins / physiology*
  • Drug Discovery
  • Genes, Dominant
  • Humans
  • Molecular Targeted Therapy
  • Mutation
  • Myositis Ossificans* / drug therapy
  • Myositis Ossificans* / genetics
  • Pyrazoles / pharmacology
  • Pyrazoles / therapeutic use
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use
  • Signal Transduction / physiology*
  • Transforming Growth Factor beta / physiology*

Substances

  • Bone Morphogenetic Proteins
  • LDN 193189
  • Pyrazoles
  • Pyrimidines
  • Transforming Growth Factor beta
  • ACVR1 protein, human
  • Activin Receptors, Type I